Visit https://www.peervoice.com/SEB860 to view the entire programme with slides. After completing “Innovation in Antibody Drug-Conjugate Engineering: Will It Pay Off?”, participants will be able to: Describe the limitations associated with current cancer therapies and the rationale for advancing antibody drug-conjugate (ADC) technology; Summarise the clinical data for the most advanced emerging ADCs in development for solid tumours; Translate how new-generation ADCs could impact current clinical practice.